Chemotherapy for colorectal cancer Journal Article
| Authors: | Kemeny, N. E.; Conti, J. A.; Bertino, J. R. |
| Article Title: | Chemotherapy for colorectal cancer |
| Abstract: | To the Editor: We believe that hepatic atrial infusion, new drugs, and biochemical modulation deserve more attention than they received in Dr. Moertel's review of chemotherapy for colorectal cancer (April 21 issue)1. With respect to hepatic arterial infusion, two large studies with a crossover design demonstrated survival advantages for patients who were crossed over from systemic to hepatic arterial chemotherapy; two studies in which there was no survival advantage associated with hepatic therapy involved only small numbers of patients2. In the study by the National Cancer Institute,2 the median survival was 22 and 12 months for the groups... © 1994, Massachusetts Medical Society. All rights reserved. |
| Keywords: | cancer chemotherapy; cancer survival; fluorouracil; antineoplastic agents; neurotoxicity; letter; colorectal cancer; liver toxicity; enzyme inhibitor; irinotecan; colorectal neoplasms; drug cost; folinic acid; colon cancer; infusions, intra-arterial; drug absorption; thymidylate synthase inhibitor; raltitrexed; levamisole; liver circulation; sparfosic acid; human; priority journal |
| Journal Title: | New England Journal of Medicine |
| Volume: | 331 |
| Issue: | 10 |
| ISSN: | 0028-4793 |
| Publisher: | Massachusetts Medical Society |
| Date Published: | 1994-09-08 |
| Start Page: | 680 |
| End Page: | 681 |
| Language: | English |
| DOI: | 10.1056/nejm199409083311018 |
| PUBMED: | 8052286 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | For original article, see PMID: 8133857, DOI: 10.1056/NEJM199404213301608 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work